Tue.Dec 05, 2023

article thumbnail

As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growth

Fierce Pharma

As Johnson & Johnson places a magnifying glass on its pharmaceutical business, the focus for the remainder of the decade rests on the shoulders of some 25 new and upcoming drugs.

Sales 299
article thumbnail

Moving Beyond Medicine To Treat Chronic Pain

MedCity News

I look at non-pharmacological approaches like digital therapeutics as having the potential to give someone like me living with chronic pain everything I need to make a healthy recovery: access to digital treatments and clinicians, to community, coaching, and navigation services.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Travere cuts workforce by 20% as Filspari's prospects are up in one rare kidney disease, down in another

Fierce Pharma

Travere Therapeutics will reduce its workforce by 20%, with the jo | Travere Therapeutics will reduce its workforce by 20%, with the job cuts focused on “non-field-based employees,” the company said on Tuesday. The layoffs are part of a shake-up of the San Diego-based company as it focuses on its launch of kidney drug Filspari and develops pegtibatinase as a potential treatment for the metabolic disorder homocystinuria (HCU).

article thumbnail

FDA Grants Breakthrough Designation to Johnson & Johnson’s Novel Treatment for HR-NMIBC

PharmExec

TAR-200 has a novel targeted releasing system for the treatment of patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer who are ineligible for bladder removal surgery.

FDA 116
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

In letter to lawmakers, cancer patient advocates call for more action in fighting drug shortages

Fierce Pharma

As the year comes to a close, shortages of key cancer drugs have no end in sight. | In its letter to congressional leaders, the American Cancer Society Cancer Action Network (ACS CAN) outlined the root causes of drug shortages and offered potential solutions. Further, the group detailed the impact of the crisis on both adult and child cancer patients.

Patients 237
article thumbnail

Phase III data for novel telomerase inhibitor released

European Pharmaceutical Review

Results from Geron’s Phase III IMerge trial evaluating its first-in-class investigational telomerase inhibitor imetelstat, have shown long-term and durable response in participants with a rare haematologic malignancy. Efficacy of the treatment was compared to placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs).

More Trending

article thumbnail

Roche to advance novel obesity and diabetes treatments

European Pharmaceutical Review

Roche has agreed to acquire biotech Carmot Therapeutics for an upfront purchase price of $2.7 billion, enabling the Swiss pharma company to add a range of incretin treatments for obesity and diabetes to its portfolio. Incretins are “gut hormones that are secreted after food intake and play a role in modulating blood glucose by stimulating insulin secretion and suppressing appetite,” Roche highlighted.

Food 110
article thumbnail

Pharma group blasts UK's drug rebate scheme shortly after lauding 'landmark' spending deal

Fierce Pharma

Despite what was presented as a “landmark” deal between the pharmaceutical companies and the government, the U.K.’s pharma association has not stopped pressuring the government for more industry-fr | Despite what was presented as a “landmark” deal between the pharmaceutical companies and the government, the U.K.’s pharma association has not stopped pressuring the government for more industry-friendly spending policies.

Pharma 144
article thumbnail

Ketryx Rakes In $14M to Speed Up Medical Device Development & Quality Assurance

MedCity News

Ketryx raised $14 million in Series A funds. The startups sells a platform — designed around FDA regulations and quality standards — that automates much of the work required from medical device companies’ development and quality teams.

Medical 110
article thumbnail

UK’s entrance into Horizon Europe finalised

European Pharmaceutical Review

With the UK set to become an associated country to Horizon Europe on 1 January 2024, the political agreement on UK’s association to Horizon Europe has been adopted. Now, this final step in the process has been implemented by the EU-UK Specialised Committee on Participation in Union Programmes (SCPUP), the European Commission (EC) has announced. The programme is the EU’s key funding initiative for research and innovation with a budget of €95.5 billion for 2021-27.

Education 105
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus

MedCity News

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Leads 112
article thumbnail

Drug Solutions Podcast: Staying on Track with Formulation of Cell Culture Media

PharmaTech

Tom Fletcher, director of Research and Development at FUJIFILM Irvine Scientific; and Bob Newman, PhD, chief scientific director at FUJIFILM Irvine Scientific, discuss formulation, specifically with how to prepare culture media for use, single use technologies, and automations to create closed systems in cell/gene therapies with former Pharmaceutical Technology editor Jill Murphy.

Media 98
article thumbnail

Expert: The Killer App of AI in Radiology Is Anything that Boosts Workflow Integration

MedCity News

The AI tools that radiologists need the most are ones that integrate their workflows and make it easier to access past images, said Dr. Jocelyn Chertoff, radiology chair at Dartmouth Health. When adopting AI to address their workforce shortage, hospitals need to involve clinicians early-on in decisions about what new tools to implement, she also noted.

113
113
article thumbnail

Q&A: Tackling the rise of fake anti-obesity drugs on the market

Pharmaceutical Technology

Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.

Marketing 111
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

How the Patient Perspective Can Drive Powerful Clinical Study Designs in Oncology

MedCity News

Regulators and experts consider patient-reported outcomes (PROs) as the gold standard when assessing a patient’s subjective treatment experience. As such, ePROs can be the key to product differentiation for sponsors seeking to highlight their product’s ease of administration, tolerability, or compatibility in combination with other components of a treatment regimen.

Patients 108
article thumbnail

Pharma accuses UK of ‘mixed messages’ on rebate schemes

pharmaphorum

The pharma industry and the UK government may have reached an accord on the voluntary scheme of rebates used to limit rises in medicines spending in the UK, but the alternative statutory scheme remains a prickly subject.

Pharma 93
article thumbnail

Amicus Leader, BIO Board Member John Crowley Named Trade Group’s New CEO

MedCity News

BIO’s new president and CEO is a familiar face. John Crowley, a longtime BIO board member, was named the life sciences industry trade group’s new leader, starting in March.

Biopharma 107
article thumbnail

Oxford Biomedica agrees to acquire ABL Europe

Pharmaceutical Technology

Oxford Biomedica has signed an agreement to acquire CDMO ABL Europe from Institut Mérieux subsidiary TSGH SAS in a deal worth €15m ($16.27m).

97
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Hims & Hers Gets Into Weight Loss Treatment

MedCity News

Hims & Hers unveiled a new weight loss program on Monday that includes access to medications, educational content and digital tracking tools.

Education 111
article thumbnail

KCL molecular communication system to revolutionise drug delivery

PharmaTimes

The platform safely and effectively replicates the electric signalling process compounds - News - PharmaTimes

105
105
article thumbnail

BMS chases MSD/Seagen with first-line bladder cancer filing

pharmaphorum

BMS chases MSD/Seagen with first-line bladder cancer filing Phil.

103
103
article thumbnail

NIHR invests £55m to tackle health inequalities and outcomes

PharmaTimes

Millions of people in the UK are set to benefit from the second wave of funding - News - PharmaTimes

99
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

A Day In The Life Of A Cardiac Rhythm Clinical Specialist With Crystal Sobande

Evolve Your Success

Being present is not just a strategy; it’s the heartbeat of professional evolution. In this episode, Crystal Sobande , Cardiac Rhythm Clinical Specialist, openly discusses her transition from selling cosmetic dermatology treatments to navigating the ever-changing world of medical devices. Discover the behind-the-scenes hustle and unpredictability as Crystal walks us through the typical day in her life.

article thumbnail

Eli Lilly Announces Availability of Obesity Drug Zepbound at US Pharmacies

PharmExec

Patients with obesity are now able to access Zepbound (tirzepatide) with a prescription at retail and mail-order pharmacies across six dose strengths.

Retail 64
article thumbnail

Roche bounces back in PIK3 with inavolisib data

pharmaphorum

Roche bounces back in PIK3 with inavolisib data Phil.

101
101
article thumbnail

Opdivo Combination Granted FDA Priority Review for Unresectable, Metastatic Urothelial Carcinoma

Pharmaceutical Commerce

Opdivo (nivolumab) plus cisplatin-based chemotherapy shows improved survival benefits in the first-line treatment of adults with unresectable or metastatic urothelial carcinoma.

FDA 52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Changes to hospital price transparency requirements address data availability and quality

Clarify Health

Since January 2021, U.S. hospitals must share clear, accessible information online about the standard charges for the services provided to improve healthcare price transparency. Unfortunately, however, compliance with CMS regulations has been lacking. As of last summer, and more than two and a half years after the enforcement date, only about a third of hospitals fully complied with hospital price transparency requirements.

article thumbnail

AI is Here – Considerations for How Your Brand’s Patient Support Services Will Be Impacted

Pharmaceutical Commerce

AI is here – are you ready? In today’s podcast we talk with Ron Lacy, Vice President of Product and Innovation from UBC about how AI is changing the services in the patient services market. We will discuss with Ron how the use of cognitive services including large language models are changing how patient support services interact with their stakeholders including patients, payers, and even prescribers while still providing exceptional support for benefit verifications, reducing time to complete

article thumbnail

Q&A: How Does a ‘Never Enough’ Achievement Culture Impact Your Workforce’s Morale? Planning for 2024 With Journalist and Author Jennifer Breheny Wallace

PharmExec

Jennifer Breheny Wallace, award-winning journalist and author, notes that C-Suite leaders should understand the financial risks of not taking action to address workplace burnout in 2024.

52
article thumbnail

Obesity Treatment Zepbound Now Available in United States

Pharmaceutical Commerce

Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.

52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A